Théodora Bejan‐Angoulvant

Rituximab and mycophenolate mofetil combination in patients with interstitial lung disease (EVER-ILD): a double-blind, randomised, placebo-controlled trial

Julie Mankikian, Agnès Caille, Martine Reynaud‐Gaubert et al. · European Respiratory Journal · 2023 · 121 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +13

The underlying inflammatory chronic disease influences infliximab pharmacokinetics

Christophe Passot, Denis Mulleman, Théodora Bejan‐Angoulvant et al. · mAbs · 2016 · 66 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

Overview of Systematic Reviews and Meta-analyses on Systemic Adverse Events Associated With Intravitreal Anti–Vascular Endothelial Growth Factor Medication Use

Marie Thulliez, Denis Angoulvant, Pierre‐Jean Pisella et al. · JAMA Ophthalmology · 2018 · 65 citations

Medicine, Ophthalmology, Pharmacotherapy +17

Cardiovascular Adverse Events With Intravitreal Anti–Vascular Endothelial Growth Factor Drugs

Nadège Ngo Ntjam, Marie Thulliez, Gilles Paintaud et al. · JAMA Ophthalmology · 2021 · 47 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +16

Immune checkpoint inhibitor-associated myocarditis: a novel risk score

John R. Power, Charles Dolladille, Benay Özbay et al. · European Heart Journal · 2025 · 40 citations · Full text

Medicine, Cardiology, Immunology +14